Search research articles
Contact Us
Filters
Showing results (101-110 of 114) with videos related to
Page
of 12
Sort By:
Medical Oncology (Northwood, London, England)
|
February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome
Eman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Urology Practice
|
October 9, 2024
Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing
Sophia M Abusamra, Marissa A Solorzano, Jake Quarles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
The Oncologist
|
October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617
Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
Transplantation Proceedings
|
June 15, 2004
Liver transplantation in pigs with small-for-size grafts: effect of portocaval shunt
P R Reichert, J S Pires, C A Sallet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
The Lancet. Oncology
|
March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
Laila A Gharzai, Ralph Jiang, David Wallington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2020
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials
William C Jackson, Holly E Hartman, Robert T Dess, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 114) with videos related to
Sort By:
Page
of 12
Medical Oncology (Northwood, London, England)
|
February 15, 2021
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome
Eman Abdulfatah, Zachery R Reichert, Matthew S Davenport, et al.
Urology Practice
|
October 9, 2024
Detection of Germline Variants in Patients With Localized and Metastatic Prostate Cancer Through Guideline-Based Testing
Sophia M Abusamra, Marissa A Solorzano, Jake Quarles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 18, 2024
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
D E Rathkopf, M R Patel, A D Choudhury, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2026
Corrigendum to "Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer": [Ann Oncol 36 (2025) 76-88]
D E Rathkopf, M R Patel, A D Choudhury, et al.
The Oncologist
|
October 22, 2025
Genomic Alterations and Associated Outcomes in Patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer treated with 177Lu-PSMA-617
Justine Panian, Nicholas C Henderson, Daniel Herchenhorn, et al.
Transplantation Proceedings
|
June 15, 2004
Liver transplantation in pigs with small-for-size grafts: effect of portocaval shunt
P R Reichert, J S Pires, C A Sallet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 24, 2024
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Charles B Nguyen, Melissa A Reimers, Chamila Perera, et al.
The Lancet. Oncology
|
March 4, 2021
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
Laila A Gharzai, Ralph Jiang, David Wallington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2020
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials
William C Jackson, Holly E Hartman, Robert T Dess, et al.
Page
of 12